Kornimate/medical-research-clean huggingface dataset:
neural basis of cognition

Conditions: Epilepsy

Summary: the overall purpose of this study is to better understand human cognition and human epilepsy by working with patients undergoing clinical treatment for pharmacologically resistant epilepsy. the investigators will investigate human cognition by conducting controlled experiments that focus on sensory, motor, and cognitive phenomena such as sensory processing, memory, and language. the investigators will also examine the neural underpinnings of epilepsy during both sleep and wakefulness to better understand both the foundations of epilepsy and how epilepsy affects cognition. the investigators hope to use these data to have a better understanding of cognition, epilepsy, and how the two interact. this will potentially lead to better markers for seizure onsets as well as epilepsy more generally. for this research, the investigators will use μecog arrays manufactured by commercial partners. these arrays have passed all major iso 10993 bio-compatibility tests. based on this characterization and use in the intraoperative setting (limited duration and supervised usage), these devices pose a minimal risk to participants. data will be analyzed and protected using the duke ssri protected research data network.


Eligibility criteria:
inclusion criteria: * potential subjects will come from adult and pediatric patients (between the ages of 12 and 18) undergoing surgery for the treatment of pharmacologically resistant epilepsy, brain tumor resection, brain mass resection, or deep brain stimulation (dbs) for the first time * proficient english speakers * no major cognitive impairment exclusion criteria: * previous dbs procedure * subject unable to consent to study
compliance of blood pressure and lipid in hypertensive patients under the management of hospitals at different levels

Conditions: Hypertension

Summary: this is a multi-center, prospective cohort study that collects only diagnostic and therapeutic data in subjects but does not interfere with treatment.

the study aims to assess blood pressure and lipid levels, the use of lipid-lowering and antihypertensive drugs, and treatment compliance and adverse events in hypertensive outpatients of 30 hospitals of different levels, following them up for 1 and 3 months after treatment, respectively. the study would reveal the compliance of blood pressure and lipid levels in hypertensive patients under management of hospitals at different levels, and analyze factors affecting blood pressure or lipid levels associated with treatment compliance. therefore, the study would provide clinical data from the real world for future prevention and control of cvd in china.

Eligibility criteria:
inclusion criteria: patients meeting the following criteria will be included: 1. age ≥18 years, male or female; 2. agreement for blood pressure and lipid testing; 3. initial diagnosis of primary hypertension, with blood pressure conforming to the diagnostic criteria of the 2018 guidelines for the prevention and treatment of hypertension in china \[14\] (with no antihypertensive drugs, sbp ≥ 140 mmhg and/or dbp ≥ 90 mmhg after three tests performed on different days); or a history of primary hypertension but incompliant blood pressure; 4. willingness to participate in the study and signing of informed consent. exclusion criteria: * patients meeting the following criteria will be excluded: 1. involvement in an interventional clinical research; 2. pregnancy or lactation in women; 3. complication with malignant tumors; 4. diagnosis of non-primary hypertension by researchers; 5. impaired cognitive ability; 6. researchers believing that the patients have other conditions not suitable for the study.
clinical benefits of additional complex fractionated atrial electrogram targeted catheter ablation for longstanding persistent atrial fibrillation

Conditions: Atrial Fibrillation

Summary: 1. purpose of the study 1) to compare clinical outcome, procedure time, complication rate of persistent atrial fibrillation patients between conventional additional linear ablation and additional complex fractionated atrial electrogram targeted catheter ablation. 2. scientific evidence of the study 1. in atrial fibrillation patients, the maintenance of normal sinus rhythm showed significant reduction of mortality. 2. drug therapy with anti-arrhythmic drug showed many complications and side effect, thus non-drug therapy such as catheter ablation is developed. 3. catheter ablation has been performed for 10years world-wide, and showed superior treatment outcome compared with drug therapy. 4. however, there are no consensus for proper ablation strategy in longstanding persistent atrial fibrillation. 5. additional ablation make extent of myocardial injury and paradoxically increase recurrence rate, thus still controversial. 6. therefore, we will compare conventional linear ablation with additional complex fractionated atrial electrogram targeted catheter ablation. 3. methods 1. treatment of all patients with atrial fibrillation is performed according to the standard treatment guideline of atrial fibrillation. 2. there is no additional blood sampling, imaging study, or any other invasive procedure according to the inclusion of the study. 4. study contents 1. to evaluate superior ablation strategy in longstanding persistent atrial fibrillation * compare conventional linear ablation with additional complex fractionated atrial electrogram targeted catheter ablation. both strategies are conventional ablation strategies being performed world-wide. 2. compare complex fractionated atrial electrogram before and after linear ablation.


Eligibility criteria:
inclusion criteria: 1) patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation exclusion criteria: 1. patients who do not agree with study inclusion 2. permanent af refractory to electrical cardioversion 3. af with valvular disease ≥ grade 2 4. patients with left atrial diameter greater than 60mm 5. patients with age less than 19

Keywords: atrial fibrillation, catheter ablation, recurrence
analgesic efficacy of mid-transverse process to pleura (mtp) block and intrathecal morphine in idiopathic scoliosis patients undergoing posterior spinal fusion

Conditions: Mid-Transverse Process Block; Intrathecal Morphine; Idiopathic Scoliosis; Posterior Spinal Fusion

Summary: the aim of this study is to compare the analgesic efficacy of mid-transverse process to pleura (mtp) block and intrathecal morphine in idiopathic scoliosis patients undergoing posterior spinal fusion surgery.

the postoperative period for idiopathic scoliosis patients undergoing posterior spinal fusion (psf) is fraught with challenges, including adequate postoperative pain control and prolonged hospitalization. intrathecal opioids have been used to manage postoperative pain in pediatric patients for a wide variety of surgeries , including adolescent and adult psf. multimodal analgesic (mma) regimens using several drugs and techniques are considered to be necessary for postoperative pain relief. the mid-transverse process to pleura (mtp) block was first described as a modified paravertebral block in 2017. the local anesthetics (las) are administered between the transverse process and the pleura. this results in a la spread to the dorsal and ventral rami in the paravertebral space through the fenestrations in the superior costotransverse ligament at the level of injection, and frequently to adjacent levels.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * both sexes. * american society of anesthesiology (asa) physical status i-ii. * idiopathic scoliosis patients undergoing posterior spinal fusion surgery. exclusion criteria: * patient with morbid obesity (body mass index \>40 kg/m2). * patients with pre-existing infection at block site. * known allergy to study drugs. * coagulation disorder. * history of psychiatric illness. * pre-existing neurological deficits. * presence of any pre-operative pain or history of chronic pain. * history of regular analgesic.
fkbp5 methylation and childhood emotional abuse in complex posttraumatic stress disorder: investigating the relationship and its predictive role in therapy outcome

Conditions: Borderline Personality Disorder; Posttraumatic Stress Disorder

Summary: the aim of this study is to investigate the role fkbp5 dna methylation levels in patients suffering from complex posttraumatic stress disorder, who participated in a 12-weeks disorder-specific dbt-ptsd inpatient treatment. dna methylation levels were measured before and after completing dbt-ptsd.

epigenetic modifications in the fkbp5 gene, which is involved in regulating the stress response, have been found to be associated with trauma-related mental disorders like posttraumatic stress disorder (ptsd). previous research has suggested that fkbp5 may also be a predictor of therapy outcomes. however, there is limited evidence regarding its relationship with complex ptsd (cptsd). this pilot study aimed to investigate the association between cptsd and fkbp5 dna methylation, as well as its predictive role in therapy outcomes among patients undergoing dialectical behavior therapy for ptsd (dbt-ptsd), a 12-week trauma-focused inpatient treatment program. 29 patients with cptsd who participated in the dbt-ptsd program were enrolled. fkbp5 dna methylation levels were measured at two cpg sites before treatment (n=25) and after completing dbt-ptsd (n=15). to assess the predictive value of fkbp5 dna methylation, we categorized the sample into responders and non-responders based on therapy outcome.

Eligibility criteria:
inclusion criteria: complex posttraumatic stress disorder with or wothout comorbid borderline personality disorder age between 18 and 65 years participiation in 12 weeks dbt-ptsd inpatient treatment exclusion criteria: acute suicidality
factor replacement in surgery

Conditions: Bleeding in Cardiac Surgery

Summary: this is a multicentre, randomized, active-control, pragmatic, phase 2 pilot study in adult cardiac surgery patients. two canadian hospitals will participate, and it is estimated that the study will take approximately 9 months to complete. approximately 120 bleeding adult cardiac surgical patients who require coagulation factor replacement during cardiac surgery will be included. patients will be randomized to receive either pcc or fp when the blood bank receives the first order for coagulation factor replacement and deems it to be in accordance with accepted clinical standards. patients will be treated according to their assigned group on the first and second times when coagulation factor replacement is ordered during the treatment period (24 hours after randomization). for any additional doses (i.e., the third dose and thereafter), patients in both groups will receive fp (in 1u increments at the discretion of the ordering physician). no other aspects of care will be modified. this pilot study aims to select a clinically relevant primary efficacy endpoint for a confirmative phase 3 study, which will subsequently aim to determine if pcc is non-inferior or superior to fp in terms of effica-cy and safety in bleeding cardiac surgical patients. in the pilot study, safety outcomes will be measured for the first 28 days, which is the duration of participation of each patient in the trial.


Eligibility criteria:
inclusion criteria: patients undergoing any index cardiac surgery with or without cpb in whom coagulation factor replacement with pcc or fp is ordered in the operating room for: 1. management of bleeding, or 2. anticipated bleeding in a patient who has 1. been on-pump for \>2 hours, or 2. undergone a complex procedure (e.g., acb + avr). coagulation factor deficiency must either be known to exist (as indicated by elevated extem clotting time \[ct\] or international normalized ratio \[inr\]), or be suspected based on the clinical situation. exclusion criteria: patients who meet any of the following criteria are not eligible for the study: 1. undergoing heart transplantation, insertion or removal of ventricular assist devices (not including intra-aortic balloon pump \[iabp\]), or repair of thoracoabdominal aneurysm 2. critical state immediately before emergency surgery with high probability of death within 24 hours of surgery (e.g., acute aortic dissection, cardiac arrest within 24 hours before start of surgery) 3. history of heparin induced thrombocytopenia 4. last preoperative inr \>1.5 and patient on warfarin 5. taken dabigatran, rivaroxaban, apixaban, or edoxaban within 48 hours of start of surgery 6. administered pcc or fp within 48 hours before start of surgery 7. history of severe allergic reaction to pcc or fp 8. refusal of allogeneic blood products due to religious or other reasons 9. known pregnancy

Keywords: frozen plasma (fp) prothrombin complex concentrate (pcc) octaplex coagulation factor replacement transfusion bleeding cardiac surgical patients pilot phase 2
physiological magnetic resonance imaging (mri) to improve carotid endarterectomy outcomes

Conditions: Carotid Stenosis; Hypoperfusion; Transient Ischemic Attack

Summary: the carotid arteries are blood vessels in the neck that supply blood to the brain. carotid stenosis disease is defined as a narrowing of these arteries due to the build up of plaque. the plaque material can also break off and move into the brain. the resulting blockage of blood supply to a portion of the brain is what causes 80% of all strokes. one treatment option is to have surgery on the carotid artery and remove the plaque. this procedure is called a carotid endarterectomy (cea). there is evidence that proves cea reduces the risk of stroke. the objective of this research project is to determine who is most likely to benefit from cea surgery.


Eligibility criteria:
inclusion criteria: * greater than 30 years of age * greater than grade 9 education level * mini-mental state exam (mmse) greater than 19 for carotid stenosis patients exclusion criteria: * history of acute stroke * history of current psychiatric disorder, such as depression or movement disorder * diagnosed alzheimer's disease or dementia
keratoconus detection using ms39 and pentacam

Conditions: Keratoconus

Summary: this retrospective study aims to investigate whether the ms39 and pentacam are delivering comparable results in the diagnosis of keratoconus. in the future, these measurement devices could be interchangeable in usage.

keratoconus is a degenerative pathology of the cornea, which tends to progress. it comes along with central and paracentral thinning of the cornea as well as with an apical protrusion of the cornea. keratoconus leads to vision loss. this pathology is diagnosed by using ce certified oct technology in order to map the topography of the cornea. this process constitutes a really important step in the line of management of the keratoconus. ms39 and pentacam are used for detection. retrospectively, data will be investigated, in order to see if these measurement devices deliver comparable results. in the future, these measurement devices could be interchangeable in usage.

Eligibility criteria:
inclusion criteria: * age older than 14 years * patients who show up at keratokonus consultation hours exclusion criteria: * age younger than 14 years * age older than 100 years

Keywords: keratoconus pentacam ms39
combining oral letrozole and clomiphene for ovarian stimulation

Conditions: Infertility

Summary: this is a pilot study evaluating the effect of a simplified low-cost (friendly) controlled ovarian stimulation using clomiphene citrate, letrozole, and low-dose hmg on the number of oocytes retrieved.


Eligibility criteria:
inclusion criteria: * women scheduled to controlled ovarian stimulation for oocyte retrieval. * body mass index: 18-35 kg/m2. * ultrasound scan up to the third day of a menstrual cycle with absence of a dominant and active follicle (follicle \>10mm and serum estradiol ≥ 40 pg/l). * signing an informed consent. exclusion criteria: * no exclusion criteria.
the milestone study

Conditions: Type 2 Diabetes Mellitus

Summary: sympathetic overactivity induces insulin resistance and type 2 diabetes mellitus (t2dm), so it is assumed that denervation might reduce sympathetic overactivity and improve glucose metabolism and insulin sensitivity. the purpose of this study is to evaluate the effects of multi-electrode catheter-based endovascular denervation on glucose metabolism and insulin sensitivity in patients with t2dm.

sympathetic overactivity induces insulin resistance and type 2 diabetes mellitus (t2dm), so it is assumed that denervation might improve glucose metabolism and insulin sensitivity. some clinical studies have shown that glucose metabolism is improved in patients with resistant hypertension both 1 and 3 months after denervation, and fasting glucose, insulin and c-peptide decreased significantly as did insulin resistance assessed by homa-ir. but in some clinical studies, denervation did not lead to a significant improvement of insulin sensitivity ≤12 months after treatment, and no effect in systemic sympathetic activity was observed after denervation. therefore, the efficacy of denervation on glucose metabolism is still in controversy. the investigators wish to investigate the effect of multi-electrode catheter-based endovascular denervation on glucose metabolism and insulin sensitivity in patients with t2dm.

Eligibility criteria:
inclusion criteria: * over 18 years and ≤ 70 years old * able and willing to provide informed consent * patients with established type ii diabetes mellitus (hba1c\>7.5%, diet or oral hypoglycaemic agents) * clinical stable as demonstrated by no change in background anti-diabetic medication in the last 30 days. * anticipated that patients are able to maintain a stable dose of medication for the duration of the study exclusion criteria: * arterial anatomy ineligible for endovascular denervation * history of prior renal artery intervention including balloon angioplasty, stenting or previous renal denervation * type 1 diabetes mellitus * pregnant, nursing or planning to be pregnant * orthostatic hypotension * egfr \<30 ml/min (mdrd formula) * patients that have allergy to contrast agent * myocardial infarction, unstable angina pectoris, coronary bypass or percutaneous angioplasty within 3 months before inclusion * cerebrovascular accidents and alimentary tract hemorrhage within 3 months before inclusion * any medical condition which, in the investigators opinion, may adversely affect the participants safety in the trial
drug-drug interaction study

Conditions: Pompe Disease

Summary: this study evaluates drug-drug interactions between at2220 (duvoglustat) and recombinant human alpha-glucosidase (rhgaa, also known as alglucosidase alfa) in participants with pompe disease.

this was a multi-center, international, open-label, two-period, fixed-sequence crossover study to evaluate the safety and pharmacokinetic effect of single ascending doses of duvoglustat on rhgaa administered 1 hour before initiation of a single rhgaa infusion. during period 1, participants received a single intravenous infusion of rhgaa. during period 2, each participant received a single oral dose of duvoglustat 1 hour prior to initiation of a single rhgaa infusion.

Eligibility criteria:
inclusion criteria: * male or female, diagnosed with pompe disease and between 18 and 65 years of age, inclusive * participant has been on a stable regimen and dose of rhgaa for at least 3 months before screening (stable regimen defined as currently receiving rhgaa every 2 weeks and stable dose defined as not varying by more than ± 10%) * participant has an estimated glomerular filtration rate (egfr) ≥ 50 ml/min at screening; egfr to be estimated using the 4-parameter modification of diet in renal disease (mdrd) equation: egfr (ml/min/1.73 m\^2) = 175 x (scr)\^(-1.154) x (age)\^(-0.203) x (0.742 if female) x (1.212 if african-american) * male and female participants of childbearing potential agree to use medically accepted methods of contraception during the study and for 30 days after study completion * participant is willing and able to provide written informed consent and is able to comply with all study procedures exclusion criteria: * participant has had a documented transient ischemic attack, ischemic stroke, unstable angina, or myocardial infarction within the 3 months before screening * participant has clinically significant unstable cardiac disease (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or new york heart association class iii or iv congestive heart failure) * participant requiring mechanical ventilation or is confined to a wheelchair * participant has a history of allergy or sensitivity to study drug (including excipients) or other iminosugars (for example, miglustat, miglitol) * participant is pregnant or breastfeeding * participant tests positive for hepatitis b surface antigen or hepatitis c antibody * participant has received any investigational/experimental drug or device within 30 days of screening * participant has any intercurrent illness or condition that may preclude the participant from fulfilling the protocol requirements or suggests to the investigator that the potential participant may have an unacceptable risk by participating in this study

Keywords: amicus therapeutics duvoglustat at2220 alpha-glucosidase alglucosidase alfa
effects of core stability exercise with pregnancy support belt in pubic symphysis dysfunction.

Conditions: Symphysis Pubis Dysfunction

Summary: symphysis pubic dysfunction is a well-known clinical problem encountered by many females during pregnancy, yet it has not received much attention in the research literature. as pubic symphysis dysfunction at times presents with severe pain while performing day to day activities and also affects significantly on quality of life in antenatal period, but its effective management remains difficult to determine as no standardized treatment protocols are available. this study may add to the growing body of knowledge in the management of spd, that if the core stability exercise alone or with the pregnancy support belts yield comparable outcomes and if one technique is superior to the other, which should be the alternative choice of therapy.

the study will be a randomized clinical trial and will be conducted in women care clinic, bahawalpur. this study will be completed in time duration of 10 months after the approval of synopsis. non-probability convenience sampling technique will be used and participants will be recruited in study after randomization. the subjects will be divided into two groups. group a will receive core stability exercises and group b will receive core stability exercises along with pregnancy support belt. the data will be assessed at the baseline and after 6th week of treatment. after data collection, the data will be analyzed by using spss version 25.

Eligibility criteria:
inclusion criteria: age 25-35 years females have pain in the region of pubic symphysis, with or without radiation to the groin. have pain during stair climbing, turning over in bed, standing on one leg. have tenderness on palpation of symphysis pubis. have positive active straight leg raise (aslr) test result exclusion criteria: medical conditions preventing use of pregnancy support belts. pregnant females having spd but with absolute contraindications to exercise. posterior (lumber spine or sacroiliac joint) pain that was considered worse than the symphysis pubis pain

Keywords: pain pregnancy exercise symphysis pubis dysfunction